文献速递心脑血管急症

长期连续心脏监测与常规护理对归因于大血管或小血管疾病的卒中患者心房颤动检出效果的影响:STROKE-AF随机临床试验

Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论对于归因于大血管或小血管疾病的卒中患者,植入式心脏监测器(ICM)较常规护理在12个月内检出更多心房颤动(12.1% vs 1.8%),但检出房颤的临床重要性尚待研究。

STROKE-AF为多中心(美国33个中心)随机(1:1)临床试验,纳入496例年龄≥60岁或50-59岁且至少1项额外卒中危险因素、归因于大血管或小血管疾病的卒中患者,且卒中发生在ICM植入前10天内。干预组(n=242)在卒中最长10天内植入ICM,对照组(n=250)接受各中心常规护理,包括外部心脏监测如12导联心电图、Holter监测、遥测或事件记录器。主要终点为12个月内检出持续时间>30秒的心房颤动;ICM组27例(12.1%)vs 对照组4例(1.8%),风险比(HR)7.4(95%CI 2.6-21.3),P<.001。221例接受ICM植入的患者中4例(1.8%)发生ICM操作相关不良事件(1例部位感染、2例切口部位出血、1例植入部位疼痛)。结论认为ICM较常规护理检出更多房颤,但检出房颤是否具有临床重要性尚需进一步研究。

要点

  • 在归因于大血管或小血管疾病的卒中患者中,ICM组12个月内房颤检出率为12.1%(27/242),对照组为1.8%(4/250),HR 7.4(95%CI 2.6-21.3),P<.001。
  • 该研究纳入年龄≥60岁或50-59岁且至少1项额外卒中危险因素、卒中发生在ICM植入前10天内的患者,中位CHA2DS2-VASc评分为5分(IQR 4-6)。
  • 221例接受ICM植入的患者中,4例(1.8%)发生ICM操作相关不良事件:1例部位感染、2例切口部位出血、1例植入部位疼痛。
  • 作者指出,检出房颤是否具有临床重要性尚需进一步研究。

适用人群与场景

  • 年龄≥60岁,或年龄50-59岁且至少1项额外卒中危险因素的缺血性卒中患者。
  • 卒中归因于大血管或小血管疾病,且卒中发生在ICM植入前10天内。
  • 研究纳入美国33个中心的496例患者,随机分为ICM组(n=242)和常规护理组(n=250)。

诊断标准与关键阈值

  • 主要终点为检出持续时间超过30秒的心房颤动,随访至12个月。

处置流程与药物剂量

  • 干预组在卒中最长10天内植入ICM。
  • 对照组接受各中心常规护理,包括外部心脏监测如12导联心电图、Holter监测、遥测或事件记录器。

研究设计与关键结果

  • STROKE-AF为随机(1:1)、多中心(美国33个中心)临床试验,2016年4月至2019年7月纳入496例患者,主要终点随访至2020年8月。
  • 492例随机患者平均(SD)年龄67.1(9.4)岁,185例(37.6%)女性,417例(84.8%)完成12个月随访;中位(IQR)CHA2DS2-VASc评分为5(4-6)。
  • 12个月时房颤检出:ICM组27例(12.1%)vs 常规护理组4例(1.8%);HR 7.4(95%CI 2.6-21.3),P<.001。
  • 221例接受ICM植入的患者中,4例(1.8%)发生ICM操作相关不良事件:1例部位感染、2例切口部位出血、1例植入部位疼痛。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:作者指出,需要进一步研究以了解在这些患者中检出房颤是否具有临床重要性。

对床旁实践的改变

  • 对于归因于大血管或小血管疾病的卒中患者,与常规护理相比,ICM监测在12个月内检出更多房颤(12.1% vs 1.8%)。
  • 作者认为,检出房颤在这些患者中是否具有临床重要性尚需进一步研究。

指南或共识出处

  • STROKE-AF随机临床试验(ClinicalTrials.gov标识符:NCT02700945)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients with ischemic stroke attributed to large- or small-vessel disease are not considered at high risk for atrial fibrillation (AF), and the AF incidence rate in this population is unknown.

OBJECTIVES: To determine whether long-term cardiac monitoring is more effective than usual care for AF detection in patients with stroke attributed to large- or small-vessel disease through 12 months of follow-up.

DESIGN, SETTING, AND PARTICIPANTS: The STROKE-AF trial was a randomized (1:1), multicenter (33 sites in the US) clinical trial that enrolled 496 patients between April 2016 and July 2019, with primary end point follow-up through August 2020. Eligible patients were aged 60 years or older or aged 50 to 59 years with at least 1 additional stroke risk factor and had an index stroke attributed to large- or small-vessel disease within 10 days prior to insertable cardiac monitor (ICM) insertion.

INTERVENTIONS: Patients randomized to the intervention group (n = 242) received ICM insertion within 10 days of the index stroke; patients in the control group (n = 250) received site-specific usual care consisting of external cardiac monitoring, such as 12-lead electrocardiograms, Holter monitoring, telemetry, or event recorders.

MAIN OUTCOMES AND MEASURES: Incident AF lasting more than 30 seconds through 12 months.

RESULTS: Among 492 patients who were randomized (mean [SD] age, 67.1 [9.4] years; 185 [37.6%] women), 417 (84.8%) completed 12 months of follow-up. The median (interquartile range) CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category) score was 5 (4-6). AF detection at 12 months was significantly higher in the ICM group vs the control group (27 patients [12.1%] vs 4 patients [1.8%]; hazard ratio, 7.4 [95% CI, 2.6-21.3]; P < .001). Among the 221 patients in the ICM group who received an ICM, 4 (1.8%) had ICM procedure-related adverse events (1 site infection, 2 incision site hemorrhages, and 1 implant site pain).

CONCLUSIONS AND RELEVANCE: Among patients with stroke attributed to large- or small-vessel disease, monitoring with an ICM compared with usual care detected significantly more AF over 12 months. However, further research is needed to understand whether identifying AF in these patients is of clinical importance.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02700945.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Bernstein RA, Kamel H, Granger CB, et al. Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial. JAMA. 2021. PMID: 34061145. doi:10.1001/jama.2021.6470

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。